Arthrogen is an Amsterdam based biopharmaceutical clinical-stage company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer.
The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.
The first target indication is in the field of rheumatic diseases. Arthrogen has started a phase 1b clinical trial in The Netherlands and in Canada.
It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.
'First cohort enrolled in trial with innovative gene therapy for arthritis.' Read the full article here.
Clinical trial ART-I02 phase Ib in NL now also open for patients with hand osteoarthritis. For more information visit proefpersoon.nl
During the BioEurope Spring held at the Rai 12-14 March, Arthrogen will be represented by Robert Jan Lamers (CEO) and Janneke Meulenberg (COO).
Arthrogen will be represented by Janneke Meulenberg (COO) and Ingrid de Vries (Research Technician) at the Cell Therapy Manufacturing & Gene Therapy Congress 6 – 7 December 2017 RAI, Amsterdam.
Robert Jan Lamers (CEO) will be present at Phacilitate Cell & Gene Therapy Europe 2017 in Berlin where Janneke Meulenberg, COO, will join the speaker panel.
Arthrogen's COO, Janneke Meulenberg, will present Wednesday September 13 a case study on: Production Platforms for RA Gene Therapy Applications at the'Cell and Gene Therapy Manufacturing' conference in London
Appeal by the Dutch Arthritis Association: http://www.reumafonds.nl/informatie-voor-doelgroepen/patienten/help-mee/neem-deel-aan-onderzoek
Arthrogen to be present at the EULAR Annual European Congress of Rheumatology, Madrid June 14-17, 2017
Arthrogen’s CEO Robert Jan Lamers to present at the May 22-23, 2017 BioEquity, Paris
Arthrogen to be present at the American Society of Gene & Cell Therapy, ASGCT annual meeting, Washington, DC May 10-13, 2017
Arthrogen’s CEO Robert Jan Lamers to present at the May 3, 2017 Investment Summit for Advanced Therapies, London
Arthrogen in the news: http://labiotech.eu/arthrogen-gene-therapy-rheumatoid-arthritis/
Arthrogen announces approval for Phase Ib study with gene therapy ART-I02 in patients with rheumatoid arthritis.
New publication: Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....
Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....
Intra-articular etanercept treatment in inflammatory arthritis...
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...
Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...